Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.pmrj.2010.03.036 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Treatment Crossover Following Advanced Therapy for Overactive Bladder Syndrome.
Urogynecology (Phila)
February 2025
From the Departments of Gynecology and Obstetrics.
Importance: Patients deciding between advanced therapies for overactive bladder syndrome may be interested to know the likelihood of treatment crossover after sacral neuromodulation, intradetrusor OnabotulinumtoxinA, or percutaneous tibial nerve stimulation. Treatment crossover was defined as a switch from one advanced therapy to another.
Objectives: The aim of this study was to estimate the rate of treatment crossover after each advanced therapy for nonneurogenic overactive bladder syndrome.
Effects and Safety of Botulinum Toxin Injection in Treatment of Androgenetic Alopecia: A Meta-analysis and Systematic Review.
Dermatol Surg
January 2025
Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, P.R. China.
Background: Androgenetic alopecia (AGA) is a prevalent condition that significantly affects the psychosocial well-being of many individuals, and its treatment remains a clinical challenge. Botulinum toxin (BTX) injections have been reported to have a therapeutic effect on AGA. Although several studies have explored the efficacy and safety of this novel treatment, most are clinical studies with small sample sizes.
View Article and Find Full Text PDFAnalysis of Research Waste in Phase III/IV Randomized Controlled Trials of Botulinum Toxin Type A.
Dermatol Surg
January 2025
All authors are affiliated with the Department of Plastic & Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Ninth People's Hospital, Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Background: The application of randomized controlled trials (RCTs) outcomes of botulinum toxin type A (BoNT-A) to actual patient care faces a significant hurdle due to research waste (RW). This includes the results of RCTs that have not been published even 4 years after completion and those with insufficiently reported outcomes and design flaws. The prevalence of RW within BoNT-A-associated RCTs remains uncertain.
View Article and Find Full Text PDFAn International Survey on the Use of a Polyrevitalizing Solution With or Without Other Aesthetic Procedures in the Daily Practice of Aesthetic Physicians.
J Cosmet Dermatol
January 2025
Department of Dermatology, University of Athens School of Medicine, Andreas Sygros Hospital, Athens, Greece.
Objective: NCTF135HA, a versatile polyrevitalizing solution, is a potent agent for enhancing skin quality, radiance, moisture, vitality, and diminishing fine wrinkles caused by aging factors. Data demonstrate a divergence in its application from skin quality enhancement to treatment of vitiligo lesions. To know more precisely about the protocol of use among providers, alone or in combination with other procedures, we performed an international survey.
View Article and Find Full Text PDFDiverse Clinical Presentation of RAC1-Related Intellectual Developmental Disorder.
Am J Med Genet A
January 2025
Hayward Genetics Center, Tulane University School of Medicine, New Orleans, Louisiana, USA.
RAC1 encodes the protein RAS-related C3 Botulinum Toxin Substrate 1 (RAC1), which plays a pivotal role in various cellular functions. Pathogenic variants in RAC1 are linked to the rare intellectual developmental disorder, autosomal-dominant 48 (MRD48). We present one case with typical phenotype and two cases with a mild phenotype.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!